CoraLite® Plus 488-conjugated KMT2C Recombinant antibody

KMT2C Recombinant Antibody for IF/ICC

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

IF/ICC

Conjugate

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

240542A2

Cat no : CL488-83595-4

Synonyms

---

Validation Data Gallery

• 

  IF Staining of MCF-7 using CL488-83595-4

  Immunofluorescent analysis of (4% PFA) fixed MCF-7 cells using CoraLite® Plus 488 KMT2C antibody (CL488-83595-4, Clone: 240542A2 ) at dilution of 1:200.

---

Tested Applications

• Positive IF/ICC detected in: MCF-7 cells

Recommended dilution

• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

The immunogen of CL488-83595-4 is KMT2C Fusion Protein expressed in E. coli.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: KMT2C fusion protein Ag28875
• Full Name: myeloid/lymphoid or mixed-lineage leukemia 3
• Calculated Molecular Weight: 541 kDa
• GenBank Accession Number: NM_170606
• Gene Symbol: KMT2C
• Gene ID (NCBI): 58508
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.